News | June 11, 2009

Covidien to Highlight Technetium-99m Development at SNM

June 12, 2009 - Covidien will be highlighting at the 2009 SNM Annual Conference in Toronto, June 13-17, its abbreviated new drug application (ANDA) for its kit for the preparation of technetium-99m (Tc-99m) sestamibi injection and radiosotope development.

Covidien's generic product is pharmaceutically equivalent to Cardiolite1, a myocardial perfusion imaging agent used for detecting coronary artery disease. With FDA approval of the ANDA, which was filed by the company's Mallinckrodt subsidiary, Covidien's generic product is now available for customers in the United States.

Covidien's will also focus on its co-marketing agreement with Siemens' PETNET to offer high and low energy radioisotopes to nuclear medicine sites. Through the agreement, Coviden Imaging Solutions and PETNET created a network of nuclear imaging product offerings to expand customer access to a wider range of products, including molecular imaging agents, or radioisotopes, designed to illuminate conditions such as cancer or heart disease when doing SPECT and PET scans.

It will also underscore its agreement with Bacock & Wilcox Technical Services Group Inc. to develop technology for the manufacture of molybdenum-99 (Mo-99), the parent isotope of Tc-99m, the most widely used radioisotope for molecular imaging and nuclear medicine procedures. This collaboration is an initial step toward establishing a large-scale U.S. supply of medical isotopes.

For more information: www.covidien.com

Related Content

Researchers Trace Parkinson’s Damage in the Heart
News | PET Imaging | July 17, 2018
A new way to examine stress and inflammation in the heart will help Parkinson’s researchers test new therapies and...
Siemens Healthineers Announces FDA Clearance of syngo.via VB30 Molecular Imaging Software
Technology | Nuclear Imaging | July 16, 2018
At the 2018 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), June 23-26 in Philadelphia...
Guerbet, IBM Watson Health Partner on Artificial Intelligence for Liver Imaging
News | Clinical Decision Support | July 10, 2018
Guerbet announced it has signed an exclusive joint development agreement with IBM Watson Health to develop an...
SNMMI Image of the Year Highlights Theranostic Approach for Advanced Prostate Cancer

IMAGE OF THE YEAR: PSMA PET before and after lutetium-177 PSMA617 theranostics in 8 patients with metastatic prostate cancer who exhausted standard therapeutic options.

68Ga-PSMA11 PET maximum intensity projection (MIP) images at baseline and 3 months after 177Lu-PSMA617 in 8 patients with PSA decline ≥ 98 percent in a prospective phase II study. Any disease with SUV over 3 is in red. Credit: Michael Hofman, John Violet, Shahneen Sandhu, Justin Ferdinandus, Amir Iravani, Grace Kong, Aravind Ravi Kumar, Tim Akhurst, Sue Ping Thang, Price Jackson, Mark Scalzo, Scott Williams and Rodney Hicks, Peter MacCallum Cancer Centre, Melbourne, Australia.

News | PET Imaging | June 29, 2018
In the battle against metastatic castrate-resistant prostate cancer, studies have demonstrated a high response rate to...
MILabs Introduces Futuristic PET Capabilities on New VECTor6 System
Technology | PET Imaging | June 28, 2018
At the 2018 Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting, June 23-26, in Philadelphia,...
Philips North America and GE Healthcare Win IMV PET Imaging ServiceTrak Awards
News | PET Imaging | June 25, 2018
IMV, part of the Science and Medicine Group and a market research and business intelligence provider to the imaging...
New ASNC SPECT Imaging Guideline Addresses Advances in Myocardial Perfusion Imaging
News | SPECT Imaging | June 21, 2018
The American Society of Nuclear Cardiology (ASNC) has published an update to its 2010 guidelines for single photon...
FDA Clears New Imaging Functionalities for Biograph mCT PET/CT Systems
Technology | PET-CT | June 21, 2018
Siemens Healthineers will announce U.S. Food and Drug Administration (FDA) clearance of four new system features for...
PET/CT Changes Care for 59 Percent of Suspected Recurrent Prostate Cancer Cases
News | Prostate Cancer | June 13, 2018
A recently presented investigational clinical trial evaluated the impact of 18F fluciclovine positron emission...
Overlay Init